Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07435129 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv3
  2. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 2026 to Jul 30, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD
Trial Details
NCT Number NCT07435129
Lead Sponsor Scholar Rock, Inc.
Conditions
(from sponsor)		 Facioscapulohumeral Muscular Dystrophy, FSHD
Related terms Muscular Dystrophy, Facioscapulohumeral
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov